Stock Quote
Cortex Pharmaceuticals, Inc. (COR) (American Stock Exchange)
$0.14
12:56pm EST
-6.03%
$0.15
$0.16
114,700
$0.16
$0.14
$0.81
$0.14
-0.11
356,909
COR
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Stoll, Roger | Chairman of the Board | 557,985 |
| Varney, Mark | President, Chief Executive Officer, Director | 728,041 |
| Messinger, Maria | Chief Financial Officer, Vice President, Corporate Secretary, Controller | 334,559 |
Profile
Cortex Pharmaceuticals, Inc. (Cortex) focuses on developing small molecule compounds that positively modulate AMPA-type glutamate receptors, a complex of proteins involved in the communication between nerve cells in the mammalian brain. These compounds, termed AMPAKINE compounds, enhance the... Full Description
Company Address
Cortex Pharmaceuticals, Inc.
15241 Barranca Parkway
Irvine CA 92618
P: +1949.7273157
F: +1949.7273657
15241 Barranca Parkway
Irvine CA 92618
P: +1949.7273157
F: +1949.7273657
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| TorreyPines Therapeutics Inc. | $3.77 | +0.27 |
| Indevus Pharmaceuticals | -- | -- |
| Spectrum Pharmaceuticals, Inc. | $4.74 | 0.00 |
| COR | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | -- | 29.90 |
| ROI(TTM) | -255.74 | 2.35 |
| ROE(TTM) | -275.83 | 3.59 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -0.25 |
| Total Revenue | $0.00M |
| Net Income | $-1.95M |
| EPS | $-0.06 |
